<p>The most consequential governance finding for Novo Nordisk is the simultaneous departure of two C-suite executives — EVP of U.S. Operations Dave Moore and EVP of Product and Portfolio Strategy Ludovic Helfgott — announced on the same day as the Q4 2025 earnings call (February 4, 2026), during the most commercially intensive period in the company's century-long history. Dave Moore oversaw the launch of Ozempic, led the acquisition of three Catalent manufacturing sites, and managed the Wegovy pill's FDA approval and U.S. launch — arguably the three most important operational achievements in recent Novo Nordisk history. His departure "for personal reasons" after just 13 months back in the EVP U.S. Operations role (he returned in January 2025 after a prior stint outside the company) raises a pattern-recognition concern: executives who leave a high-performing company twice typically have unresolved tensions with leadership or strategy. Ludovic Helfgott, who built the rare disease business from scratch over seven years, was in the Product and Portfolio Strategy role for only 10 months before departing. Two simultaneous senior departures, each with different stated reasons ("personal reasons" and "new opportunities"), occurring alongside a CEO transition (Mike Doustdar replaced Lars Fruergaard Jørgensen just five months earlier in August 2025) and a company-wide restructuring that eliminated 9,000 employees — this is not business as usual. It is the governance equivalent of a three-car pileup.</p> <p>The second critical finding is the Novo Nordisk Foundation's controlling ownership structure, which creates a governance dynamic unlike any other large-cap pharmaceutical company. The Novo Nordisk Foundation controls approximately 29% of shares and a majority of voting rights through the dual-class A/B share structure (A shares carry 10 votes each, B shares carry 1 vote each). This means no hostile takeover is possible, no activist can force strategic change, and management effectively serves at the pleasure of the Foundation rather than public shareholders. This is a double-edged sword: the Foundation provides long-term strategic stability (evidenced by the company's century of metabolic disease focus without the diversification into cosmetics, consumer health, or unrelated M&amp;A that has destroyed value at other pharmaceutical companies), but it also eliminates the market discipline that forces underperforming management to respond to shareholder pressure. At a moment when the company needs commercial execution at peak intensity — Wegovy pill launch, CagriSema approval, Medicare coverage implementation, 35+ country expansion — the absence of external accountability mechanisms becomes a governance risk rather than a governance strength.</p> <p>The third finding is the most positive: the capital allocation record over the past decade is genuinely excellent. Shares outstanding declined from 5,142 million (2015) to 4,441 million (2025) — a 13.6% reduction — while DKK 300+ billion was returned to shareholders through dividends and buybacks. The company avoided the value-destructive diversification acquisitions that plague pharmaceutical peers. R&amp;D spending was disciplined and productive, generating semaglutide, CagriSema, and zenagamtide internally rather than through serial expensive acquisitions. The one large external deal — the Catalent manufacturing sites — was strategic and directly addressed the most critical operational bottleneck. Management has historically acted as disciplined capital stewards, which provides meaningful comfort even as the leadership transition creates near-term uncertainty.</p>